Figures
Abstract
Purpose
We tested the hypothesis that high plasma YKL-40 and IL-6 associate with pancreatic cancer and short overall survival.
Patients and Methods
In all, 559 patients with pancreatic cancer from prospective biomarker studies from Denmark (n = 448) and Germany (n = 111) were studied. Plasma YKL-40 and IL-6 were determined by ELISAs and serum CA 19.9 by chemiluminescent immunometric assay.
Results
Odds ratios (ORs) for prediction of pancreatic cancer were significant for all biomarkers, with CA 19.9 having the highest AUC (CA 19.9: OR = 2.28, 95% CI 1.97 to 2.68, p<0.0001, AUC = 0.94; YKL-40: OR = 4.50, 3.99 to 5.08, p<0.0001, AUC = 0.87; IL-6: OR = 3.68, 3.08 to 4.44, p<0.0001, AUC = 0.87). Multivariate Cox analysis (YKL-40, IL-6, CA 19.9, age, stage, gender) in patients operated on showed that high preoperative IL-6 and CA 19.9 (dichotomized according to normal values) were independently associated with short overall survival (CA 19.9: HR = 2.51, 1.22–5.15, p = 0.013; IL-6: HR = 2.03, 1.11 to 3.70, p = 0.021). Multivariate Cox analysis of non-operable patients (Stage IIB-IV) showed that high pre-treatment levels of each biomarker were independently associated with short overall survival (YKL-40: HR = 1.30, 1.03 to 1.64, p = 0.029; IL-6: HR = 1.71, 1.33 to 2.20, p<0.0001; CA 19.9: HR = 1.54, 1.06 to 2.24, p = 0.022). Patients with preoperative elevation of both IL-6 and CA 19.9 had shorter overall survival (p<0.005) compared to patients with normal levels of both biomarkers (45% vs. 92% alive after 12 months).
Citation: Schultz NA, Christensen IJ, Werner J, Giese N, Jensen BV, Larsen O, et al. (2013) Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer. PLoS ONE 8(6): e67059. https://doi.org/10.1371/journal.pone.0067059
Editor: Xiao-Ping Miao, MOE Key Laboratory of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, China
Received: February 23, 2013; Accepted: May 13, 2013; Published: June 26, 2013
Copyright: © 2013 Schultz et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was supported by grants from “The Research Council at Herlev Hospital” and the ”Joint Proof-of-Concept Fund, the Ministry of Science, Technology and Innovation, Denmark”. Quidel provided the study with some of the YKL-40 ELISA kits. The study sponsors had no role in the design and conduct of the study; in the collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript. The authors had full access to all the data in the study and had the final responsibility for the decision to submit the manuscript for publication. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors declare that the study was supported by grants from “The Research Council at Herlev Hospital" and the “Joint Proof-of-Concept Fund, the Ministry of Science, Technology and Innovation, Denmark”. Quidel provided the study with some of the YKL-40 ELISA kits. The study sponsors had no role in the design and conduct of the study; in the collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript. The authors had full access to all the data in the study and had the final responsibility for the decision to submit the manuscript for publication. There is no patent for plasma YKL-40 or IL-6 analysis for pancreatic cancer. Julia S. Johansen and Paul Price developed the monoclonal and the polyclonal antibodies used in the ELISA from Quidel. University of California, San Diego, USA has a patent regarding YKL-40 as a biomarker and receive royalties from Quidel. Julia S. Johansen does not receive royalties from UCSD, since she has donated all royalties to the “YKL-40 Foundation” which donate travel grants to patients with cancer. For many years Julia S. Johansen received each year some YKL-40 kits from Quidel without cost, but she also bought some of the kits from Quidel. There is no contract between Julia S. Johansen and Quiedel.
Introduction
Surgery is the only potential curative therapy for patients with pancreatic cancer (PC). Most patients have locally advanced or metastatic PC at time of diagnosis and surgery is possible in less than 20% [1]. New biomarkers for early diagnosis and guidance of treatment for patients with PC are urgently needed [2]. Not all patients with PC have elevated serum CA 19.9, but this biomarker has a prognostic value and is used mainly to guide treatment and follow-up of patients with PC [3], [4].
Plasma concentrations of YKL-40 and IL-6 are emerging as new biomarkers in patients with cancer (5,6). YKL-40 (chitinase 3-like 1, CHI3L1) is a highly conserved glycoprotein produced by cancer cells (including PC), macrophages, neutrophils, and by fetal and embryonic stem cells (5,7–9). IL-6 and hypoxia stimulate YKL-40 production (10,11). YKL-40 regulates vascular endothelial growth factor (12,13), activates Akt signaling [20], protects against apoptosis [21], and plays a role in inflammation [5], [14], [15], bacterial clearance during infections [16], angiogenesis [12], [13], [17]–[19], cell proliferation and differentiation [8], [9], and remodeling of the extracellular matrix [5]. Plasma YKL-40 is elevated in some patients with PC, and in a proximity ligation assay study, the combination of plasma YKL-40, osteopontin, and CA 19-9 improved the diagnostic accuracy compared to CA 19-9 alone [22]. Furthermore, high plasma YKL-40 in subjects from the general population is associated with increased risk of and death from gastrointestinal cancer, including PC [23].
Interleukin-6 (IL-6) is produced by cancer cells (including PC), macrophages, lymphocytes, and endothelial cells [6], [24]–[26]. IL-6 plays a role in inflammation, acute-phase response, and development of cachexia, acts as a paracrine and autocrine growth factor for cancer cells, and inhibits radio- and chemotherapy-induced apoptosis of PC cells [6], [25], [27], [28]. High plasma IL-6 is associated with poor prognosis in patients with PC and is an independent prognostic biomarker [29].
A pilot study has shown that plasma concentrations of YKL-40 and IL-6 are elevated in patients with upper gastrointestinal cancers including patients with PC. Furthermore, changes in plasma YKL-40 and IL-6 during treatment were related to outcome [30]. In the present study, we tested the hypotheses: 1) elevated plasma concentrations of YKL-40 and IL-6 in combination with serum CA 19.9 can be used to diagnose patients with PC; and 2) elevated pre-treatment plasma YKL-40 and IL-6 predict poor prognosis. To do this, we studied 559 patients with PC from two large prospective biomarker studies in Denmark and Germany.
Patients and Methods
Patient Characteristics
BIOPAC study.
From July 1, 2008 through June 30, 2012, pretreatment blood samples were collected from 448 patients diagnosed with PC recruited consecutively from six hospitals in Denmark (Herlev University Hospital n = 224, Odense University Hospital n = 94, Rigshospitalet n = 57, Hillerød Hospital n = 29, Aalborg Hospital n = 22, and Næstved Hospital n = 22). The patients were included in the Danish multicenter BIOPAC Study “BIOmarkers in patients with PAncreatic Cancer (BIOPAC) – can they provide new information of the disease and improve diagnosis and prognosis of the patients?”. Clinical eligibility criteria for inclusion were age over 18 years and histological or cytological confirmed pancreatic adenocarcinomas. Forty-two patients with local PC underwent a pancreaticoduodenectomy, a distal pancreatectomy, or a total pancreatectomy, and 37 of these patients received adjuvant gemcitabine after operation. Three-hundred-ninety patients with locally advanced or metastatic PC received first line palliative gemcitabine (n = 361), gemcitabine in combination with capecitabine (n = 17), gemcitabine in combination with erlotinib (n = 1), 5-FU in combination with irinotecan and oxaliplatin (n = 6), or chemo-radio therapy (n = 5) until disease progression. Sixteen patients (all non-operable) received no treatment. Table 1 shows the clinical characteristics of the patients with PC. Patients were followed until death or October 6, 2012. CT scans were performed every 3rd month or on suspicion of disease progression. All patients provided written informed consent. The “BIOPAC Study” was approved by the Regional Ethics Committee (VEK ref. KA-20060094) and the Danish Data Protection Agency.
Heidelberg study.
From August 2003 through November 2009, pretreatment blood samples were collected from 111 patients diagnosed with PC and recruited consecutively at Department of General, Visceral, and Transplant Surgery, University of Heidelberg, Germany. Clinical eligibility criteria for inclusion were age over 18 years, histologically confirmed PC, undergone surgery with radical intention for PC, and adequate organ function. Only one of the patients was found non-resectable during surgery. After operation, 107 patients received adjuvant gemcitabine. Patients were followed until death or October 7, 2011. All patients provided written informed consent, and the study (including biomarker analysis) was approved by the regional ethics committee.
Biomarker Analysis
Standard operating procedures were used for blood sampling. Blood for serum and EDTA plasma were centrifuged within ½-2 hours after blood sampling and then stored at −80°C until analysis. Plasma concentrations of YKL-40 and IL-6 were determined in duplicate by commercial enzyme-linked immunosorbent assays (ELISA) (YKL-40: Quidel, Santa Clara, CA, USA; IL-6: Catalogue number HS600, R&D Systems, Abingdon, Oxon, UK) according to the manufacturers’ instructions. YKL-40 ELISA characteristics: Detection limit 20 µg/l, and intra- and inter-assay coefficients of variation (CVs) were <5% and <6% [30]. IL-6 ELISA characteristics: detection limit 0.01 ng/l, and intra- and inter-assay CVs were ≤ 8% and ≤ 11% [31]. Serum CA 19.9 was analyzed using the Immulite 2000 GI-MA (Siemens, Catalogue Number L2KG12) assay, a solid-phase, two-site sequential chemiluminescent immunometric assay.
YKL-40, IL-6, and CA 19.9 in Healthy Subjects and Patients with Chronic Pancreatitis
Healthy subjects.
The reference interval for plasma YKL-40 was determined in 3,130 healthy subjects (1293 men, 1837 women) aged 21–84 years from the Danish general population, the Copenhagen City Heart Study. They had no known disease at time of blood sampling in 1991–1994 and remained healthy and alive during the 16-year follow-up period [31]. The median plasma YKL-40 in these 3,130 healthy subjects was 40 µg/l (min-max: 20–1098 µg/l; 5–95% percentile range, 20 to 116 µg/l). The reference interval for plasma IL-6 was determined in 318 healthy blood donors (196 men, 122 women) aged 18–64 years. These subjects were all healthy, were not on medication, and had no signs or clinical symptoms of disease. The median plasma IL-6 in these 306 healthy subjects was 1.3 ng/l (min-max: 0.33–26 ng/l; 5–95% percentile range, 0.63 to 4.50 ng/l) [32]. The upper normal limit for serum CA 19.9 was 37 KU/l according to the manufacturer. The reference intervals for serum CA 19.9 for the ROC curves were determined in 142 healthy blood donors (72 men, 70 women) aged 41–66 years (median 57 years). These subjects were healthy, were not on medication, and had no signs or clinical symptoms of disease. The median serum CA 19.9 in these 142 healthy subjects was 4.25 KU/l (min–max: 2.50–77 KU/l; 5–95% percentile range, 2.50 to 28 KU/l).
Patients with chronic pancreatitis.
The reference intervals for plasma YKL-40, IL-6 and serum CA 19.9 were determined in 80 patients with chronic pancreatitis (58 men, 22 women) aged 32–85 years. The median plasma YKL-40 was 102 µg/l (min-max: 20–1661 µg/l; 5–95% percentile range, 22 to 1047 µg/l). The median serum IL-6 was 3.5 ng/l (min–max: 0.51–64.7 ng/l; 5–95% percentile range, 0.81 to 12.75 ng/l), and the median serum CA 19.9 was 15 KU/l (min–max: 2.5–1134 KU/l; 5–95% percentile range, 2.5 to 287 KU/l).
Statistical Analysis
The results of this project are reported in accordance with the REMARK guidelines [33]. Descriptive statistics for continuous variables are presented by their median levels and range. Analyses comparing patients to normal reference levels were done using logistic regression analysis. Results are presented by the receiver operating characteristics curve (ROC) and discrimination assessed by the area under the ROC (AUC). Similar analyses were done on subsets of patients. For correlations we used Spearman’s rank correlations.
Duration of survival was updated October 6, 2012 (BIOPAC Study) and October 7, 2011 (Heidelberg Study). Cases in which patients were alive on this date were censored. The primary endpoint was overall survival (OS). Survival probabilities for OS were estimated by the Kaplan-Meier method, and tests for differences between strata were done using the log-rank statistic. Graphical presentation using Kaplan-Meier estimates of OS was shown grouping patients by high vs. normal plasma YKL-40, IL-6, and serum CA 19.9 level. The Cox proportional hazards model was used for analysis of time to death, adjusting the model for stage, age, and gender. The levels of the biomarkers were analyzed either by the dichotomized value using the 95th percentile of reference data as the cut-point or by the actual value of the biomarker on the log scale (log base 2). Univariate and multivariate analyses were performed. Tests for potential interactions were done where applicable. Model assessment was done using graphical methods, Schoenfeld and Martingale residuals. P-values less than 5% were considered significant. All calculations were performed using SAS (version 9.1, SAS Institute, Cary, NC, USA).
Results
YKL-40, IL-6 and CA 19.9 and Risk of PC
Table 1 gives the clinical characteristics of the 559 patients with PC. Pre-treatment plasma YKL-40, IL-6, and serum CA 19.9 were elevated in 36%, 54%, and 82% of all patients with PC, respectively. Plasma YKL-40, IL-6 and serum CA 19.9 increased with increasing stage (Supplementary Table 1 and Supplementary Figure 1). Elevated serum CA 19.9 was found in 52% with stage IA, IB, and IIA, 76% with stage IIB, 85% with stage III, and 89% with stage IV. Fewer patients had elevated plasma YKL-40 (29%, 26%, 26%, and 46% for the different stages) and IL-6 (41%, 39%, 44%, and 66%) (Supplementary Table 1). Plasma YKL-40 and IL-6 were elevated in 35% and 42% of PC patients with normal serum CA 19.9. Fifty-two percent of patients with PC with normal CA 19.9 had either elevated plasma YKL-40 or IL-6. Ninety-two percent of all patients with PC had increased concentration of at least one of these three biomarkers.
The OR for prediction of PC in the whole study population was significant for all three biomarkers, with serum CA 19.9 having the highest AUC (serum CA 19.9: OR = 2.28, 95% confidence interval (CI), 1.97 to2.68, p<0.0001, AUC = 0.94; plasma YKL-40: OR = 4.50, 3.99–5.08, p<0.0001, AUC = 0.87; and plasma IL-6: OR = 3.68, CI 3.08 to 4.44, p<0.0001, AUC = 0.87). The ROC curves are shown in Figure 1.
In patients undergoing surgery for PC, pre-treatment plasma YKL-40 correlated with plasma IL-6 (rho = 0.45, p<0.0001), serum CA 19.9 (rho = 0.40, p<0.0001) and age (rho = 0.40, p<0.0001). Lower correlations were found between plasma IL-6 and CA 19.9 (rho = 0.21, p = 0.03) and age (rho = 0.18, p = 0.052) and between serum CA 19.9 and age (rho = 0.29, p = 0.0021). In the patients not operated on, (stage IIB, III, and IV) pre-treatment plasma YKL-40 correlated with plasma IL-6 (rho = 0.51, p<0.0001) and age (rho = 0.21, p<0.0001), but not with serum CA 19.9 (rho = 0.079, p = 0.12). Low correlations were found between plasma IL-6 and CA 19.9 (rho = 0.22, p<0.0001). No correlations were found between age and plasma IL-6 (rho = 0.03) and serum CA 19.9 (rho = 0.02).
YKL-40, IL-6 and CA 19.9 in Patients with Chronic Pancreatitis
Patients with chronic pancreatitis had higher plasma YKL-40 (median 102 µg/l, 35% had elevated level compared to upper normal level), IL-6 (3.5 ng/l, 27%) and serum CA 19-9 (15 KU/l, 25%) compared to healthy subjects. Patients with chronic pancreatitis had significantly lower concentrations of all three biomarkers compared to patients with PC (all stages combined) (YKL-40 p = 0.047; IL-6 p<0.0001; CA 19-9 p<0.0001) (Supplementary Figure 1).
OS and Pre-treatment YKL-40, IL-6 and CA 19.9 in Patients Operated for PC
Univariate Cox analysis of patients undergoing surgery for PC showed that elevated pre-treatment plasma IL-6 and serum CA 19.9 (dichotomized according to normal levels), but not plasma YKL-40 were associated with short OS, Table 2. Multivariate Cox analysis including plasma YKL-40, IL-6, serum CA 19.9, stage, age, and gender showed that IL-6 and CA 19.9 (dichotomized according normal levels) were independent biomarkers of OS, Table 2. Similar results were found if IL-6 and CA 19.9 were included as continuous log-transformed values (Table 2).
Figure 2 illustrates the Kaplan-Meier curves for patients undergoing surgery according to normal or elevated plasma YKL-40 (2A), IL-6 (2B), and serum CA 19.9 levels (2C). Patients with normal IL-6 and CA 19.9 had significantly longer OSs compared to patients with elevated levels. Figure 2D shows that the median OS was only 11.8 months (95% CI, 7.8 to18.8; and 45% alive after 1 year (95% CI, 25 to 63%)) if both IL-6 and CA 19.9 were elevated. The median survival was not reached in the group of patients with both normal IL-6 and CA 19.9 (first quartile 30.4 months, 95% CI, 11.0 to 33.7; with 92% alive after 1 year (95% CI, 71 to 98%)). The log-rank statistic demonstrated a significant difference (p<0.005) between survivals in these two groups.
D shows the survival curves for no elevated biomarkers (yellow), only elevated IL-6 (blue), only elevated CA 19.9 (green), or both IL-6 and CA 19.9 elevated (purple). The P-value refers to the log-rank test for equality of strata. Patients were dichotomized by the upper normal level for each biomarker.
OS and pre-treatment YKL-40, IL-6, and CA 19.9 in patients with PC not undergoing surgery.
Univariate Cox analysis of patients with PC not undergoing surgery showed that elevated pre-treatment plasma YKL-40, IL-6, and serum CA 19.9 (dichotomized according to normal levels) were associated (p<0.0001) with short OS, Table 3. Multivariate Cox analysis including YKL-40, IL-6, CA 19.9, stage, age, and gender showed that YKL-40, IL-6, and CA 19.9 (dichotomized according normal levels) were independent biomarkers of OS, Table 3. Similar results were found if YKL-40, IL-6 and CA 19.9 were included as continuous log-transformed values (Table 3).
Figure 3 illustrates the Kaplan-Meier curves for patients with stage IIB and III not undergoing surgery according to normal or elevated plasma YKL-40 (3A), IL-6 (3B) and serum CA 19.9 levels (3C). Patients with normal YKL-40, IL-6, and CA 19.9 had significantly longer OS than did patients with elevated levels. Figure 3D illustrates that the median OS was only 7.5 months (95% CI, 2.3 to 10.6; and 20% alive after 1 year) if all three biomarkers were elevated versus 34.4 months (7.2 to 51.1; and 90% alive after 1 year) if all three biomarkers were normal (p = 0.003).
D shows the survival curves for 0–3 elevated biomarkers. The P-value refers to the log-rank test for equality of strata. Patients were dichotomized by the upper normal level for each biomarker.
Figure 4 illustrates the Kaplan-Meier curves for patients with stage IV not undergoing surgery according to normal or elevated plasma YKL-40 (4A), IL-6 (4B), and serum CA 19.9 levels (4C). Patients with normal YKL-40, IL-6, and CA 19.9 had significantly longer OS than patients with elevated levels. Figure 4D illustrates that the median OS was only 3.0 months (2.2–3.9; and 13% alive after 1 year) if all three biomarkers were elevated versus 10.0 months (3.9–12.9; and 39% alive after 1 year) if all three biomarkers were normal (p<0.0001).
D shows the survival curves for 0–3 elevated biomarkers. The P-value refers to the log-rank test for equality of strata. Patients were dichotomized by the upper normal level for each biomarker.
Supplementary Figure 2 shows the Kaplan-Meier curves for all patients with stages IIB, III, and IV combined.
Discussion
We investigated the diagnostic and prognostic value of plasma concentrations of YKL-40 and IL-6 in 559 patients with PC included in two large prospective biomarker studies of patients with PC from Denmark and Heidelberg. The results were compared with those of serum CA 19.9. Thirty-six percent had elevated YKL-40, and 54% of all patients with PC had elevated plasma IL-6. Although the levels of both biomarkers increased with increasing tumor stage, they cannot be used alone for early diagnosis of PC, and serum CA19.9 had highest OR for prediction of PC.
IL-6 stimulates production of YKL-40, and a correlation was found between these two biomarkers. Plasma YKL-40 and IL-6 could be valuable diagnostic biomarkers in Lewis antigen-negative patients with PC and normal serum concentrations of CA 19.9 [29], since 52% of these patients had elevated YKL-40 or IL-6. The tumor volume in PC is often modest, but the frequency of patients with elevated plasma YKL-40 is higher than in patients with other solid tumors and hematologic malignancies [5], [34]. A higher percentage of patients with elevated plasma YKL-40 [35] is seen only in ovarian cancer.
High plasma concentrations of YKL-40 and IL-6 are independent prognostic biomarkers associated with short OS in patients with many different types of cancer, but only a few studies have evaluated the prognostic value of plasma YKL-40 and IL-6 in patients with PCs [34]. The main results of our study of patients with PC are that high (i.e. compared to normal values) pre-operative plasma IL-6 and serum CA 19.9 levels were independent prognostic biomarkers of short OS. If both plasma IL-6 and serum CA 19.9 were elevated before surgery, the patients had shorter OS than patients with normal biomarkers level (45% vs. 92% alive after 1 year). Multivariate Cox analysis showed that plasma YKL-40, IL-6 and serum CA 19.9 were all independent prognostic biomarkers of OS in patients with locally advanced or metastatic PC. In these patients, high levels of all three biomarkers identified a subgroup of patients with a very short median survival, i.e. only 7.5 months, vs. 34.4 months if all biomarkers were normal in patients with stage IIB and III, and 3.0 months vs. 10.0 months if all biomarkers were normal in patients with stage IV. IL-6 stimulates YKL-40 production, and in most types of cancer the proportion of patients with elevated plasma concentrations of YKL-40 is much higher in patients with metastatic disease than in patients with localized disease [5], [10]. This may explain why plasma YKL-40 in the present study was an independent prognostic biomarker of OS in patients with locally advanced or metastatic PC but not in patients with localized PC that have been operated.
There is an increasing interest for the tumorigenic microenvironment [36], [39]. An important part of this microenvironment is a tumor promoting inflammation and a varying density of infiltration of immune cells [36]. PC is characterized by scattered cancer cells embedded in a fibrotic desmoplastic stroma [40]. Neither YKL-40 nor IL-6 is a cancer-specific biomarker, and both are produced by cancer cells and inflammatory cells and are biomarkers of inflammation and tissue remodeling [3], [5], [6], [14], [15], [41]–[43]. Elevated plasma YKL-40 is found in a subset of patients with cancer and patients with non-malignant diseases characterized by inflammation and/or tissue remodeling [5]. Recent studies have implicated YKL-40 in several biological processes such as inflammation, angiogenesis, apoptosis, cell proliferation, differentiation, and regulation of extracellular tissue remodeling [5], [7]–[21], all processes important for the progression of cancer cell growth, tumor angiogenesis, and metastatic potential [36]–[38]. However, further studies are required to completely understand the functions of YKL-40 in cancer development and progression. In the general population, elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and a poor OS in these patients [23], but serum YKL-40 has little diagnostic value for early diagnosis of hepato-biliary cancer [44].
IL-6 is produced by cancer cells, including PC, macrophages, lymphocytes, and endothelial cells [6], [24]–[26]. IL-6 plays a role in inflammation and the acute-phase response, acts as a paracrine and autocrine growth factor for cancer cells, and inhibits radio- and chemotherapy-induced apoptosis of PC cells [6], [25], [27], [28], [43]. The presence of stromal desmoplasia is a hallmark in PC, driven by the pancreatic stellate cells and its interactions with cytokines like IL-6 [45]. Cachexia in patients with PC and other cancers is also regulated by IL-6 [24], [46], [47].
Recently, genome-wide association studies [48], [49] have identified SNPs (single nucleotide ploymophisms) associated with susceptibility to PC. Some SNPs are related to plasma concentrations of CA 19.9 in healthy subjects, but no association was found between these SNPs and PC. It is not known whether certain SNPs in the YKL-40 and IL-6 genes are associated with PC.
The strength of our study is its prospective design and that YKL-40 and IL-6 measurements in plasma were determined blindly, i.e. without knowledge of clinical data and the OS of the patients. Misclassification of YKL-40 and IL-6 levels will always occur to some extent even though we measured all samples in duplicate and had low coefficients of variation. The pre-treatment plasma concentrations of YKL-40 in the patients with PC were dichotomized according to the 95% upper normal YKL-40 level in a large group of 3,130 healthy subjects from the Danish general population [31]. Since plasma YKL-40 increases with age, we used age-corrected plasma YKL-40 levels. The cohort of our normal subjects is quite unique; they had no known disease at time of blood sampling in 1991–1994 and remained healthy and alive during the 16-year follow-up period [30]. We therefore consider that our classifications of PC patients with normal and elevated plasma YKL-40 are correct. Plasma concentrations of IL-6 do not increase with age, and we think that the number of healthy subjects used to determine the normal range of plasma IL-6 is sufficient.
In conclusion, plasma YKL-40 and IL-6 alone are not useful as new diagnostic biomarkers to identify patients with PC at an early stage or to discriminate between patients with PC and chronic pancreatitis. Serum CA 19-9 was the best diagnostic biomarker. However, plasma concentrations of YKL-40 and IL-6 may provide information in the subgroup of patients with PC and normal serum CA 19.9, since YKL-40 or IL-6 was elevated in 52% of these patients. In the group of patients with PC undergoing to surgery, a high pre-operative plasma IL-6 and serum CA 19.9 identified a sub-group of patients with very short survival. Future studies could test whether these patients may benefit from neo-adjuvant chemotherapy. Ninety-two percent of our patients with locally advanced or metastatic PC were treated with first line palliative monotherapy with gemcitabine, and if all three biomarkers were elevated in these patients, their prognosis was dismal. It is not known whether this subgroup of patients with PC and very poor prognosis could have benefited from a more aggressive therapy, such as FOLFIRINOX or abraxane.
Supporting Information
Figure S1.
Box-plots of pre-treatment plasma YKL-40 (A), plasma IL-6 (B) and serum CA 19.9 (C) in patients with PC according to stage and in patients with chronic pancreatitis. The median value is the line in the middle of the box and the 25th and 75th percentile are the lower and upper part of the box. The whiskers are the 5th and 95th percentiles. Outliers are given as dots.
https://doi.org/10.1371/journal.pone.0067059.s001
(PDF)
Figure S2.
Kaplan-Meier survival curves showing the association between pre-treatment plasma YKL-40 (A), plasma IL-6 (B) and serum CA 19.9 (C) in non-operated patients with PC stage IIB, III and IV. D shows Kaplan-Meier survival curves for 0–3 elevated biomarkers. The P-value refers to the log-rank test for equality of strata. Patients were dichotomized by the upper normal level for each biomarker.
https://doi.org/10.1371/journal.pone.0067059.s002
(PDF)
Table S1.
Pre-treatment plasma YKL-40, IL-6 and serum CA 19.9 in patients with PC according to stage.
https://doi.org/10.1371/journal.pone.0067059.s003
(DOCX)
Acknowledgments
Many thanks to the biomedical laboratory scientists Tonni Løve Hansen, Dorthe Mogensen, Ulla Kjærulff-Hansen, Beata Gregersen, Charlotte Falk, and Vibeke Hinzte Holm, Herlev Hospital; Teresa Rozenfeld, Glostrup Hospital; Torben Kibøl and Palle L. Pedersen, Næstved Hospital; and the staffs at the departments of Clinical Biochemistry at Herlev Hospital, Hillerød Hospital, Aalborg Hospital, and Heidelberg University Hospital for excellent technical assistance with collection of blood samples. Thanks to the Department of Clinical Biochemistry, Herlev Hospital, for measurement of serum CA 19-9. We also thank the nurses and doctors at the participating centers for inclusion of the patients in the “BIOPAC study”. The patients are thanked for their willingness to participate.
Author Contributions
Conceived and designed the experiments: NAS JSJ. Performed the experiments: NAS JKB NG JSJ. Analyzed the data: NAS IJC JSJ. Contributed reagents/materials/analysis tools: NAS JW NG BVJ OL JKB PP DC SEN MY NHH MW SEB KN JSJ. Wrote the paper: NAS IJC JSJ.
References
- 1. Siegel R, Naishadham D, Jemal A (2012) Cancer Statistics, 2012. CA Cancer J Clin 62: 10–29.
- 2. Hidalgo M (2010) Pancreatic Cancer. Review. N Engl J Med 362: 1605–1617.
- 3.
Seufferlein T, Bachet JB, Van Custem E, Rougier P on behalf of the ESMO Guidelines Working Group. Pancreatic adenocarcinoma: (2012) ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23 (Supplement 7): vii 33–40.
- 4. Ballehaninna UK, Chamberlain RS (2012) The clinical utility of CA 19–9 in diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol 3: 105–119.
- 5. Johansen JS, Schultz NA, Jensen BV (2009) Plasma YKL-40: a potential new cancer biomarker? Future Oncol 5: 1065–1083.
- 6. Guo Y, Xu F, Lu T, Duan Z, Zhang Z (2012) Interleukin-6 pathway in targeted therapy for cancer. Cancer Treat Rev 38: 904–910.
- 7. Rehli M, Krause SW, Andreesen R (1997) Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 43: 221–225.
- 8. Johansen JS, Høyer PE, Larsen LA, Price PA, Møllgård K (2007) YKL-40 protein expression in the early developing human musculoskeletal system. J Histochem Cytochem 55: 1213–1228.
- 9.
Brøchner CB, Johansen JS, Larsen LA, Bak M, Mikkelsen HB, et al.. (2012) YKL-40 is differentially expressed in human embryonic stem cells and in cell progeny of the three germ layers. J Histochem Cytochem 60; 188–204.
- 10. Nielsen AR, Plomgaard P, Krabbe KS, Johansen JS, Pedersen BK (2011) IL-6, but not TNFalfa, increases plasma YKL-40 in human subjects. Cytokine 55: 152–155.
- 11. Junker N, Johansen JS, Hansen LT, Lund EL, Kristjansen PEG (2005) Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Science 96: 183–190.
- 12. Francescone RA, Scully S, Faibish M, Taylor SL, Oh D, et al. (2011) Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem 286: 15332–15343.
- 13. Faibish M, Francescone R, Bentley B, Yan W, Shao R (2011) A YKL-40 neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol Cancer Ther 10: 742–751.
- 14. Lee CG, Da Silva C, Dela Cruz CS, Ahangari F, Ma B, et al. (2011) Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodelling, and injury. Annu Rev Physiol 73: 479–501.
- 15. Eurich K, Segawa M, Toei-Shimizu S, Mizoguchi E (2009) Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells. World J Gastroenterol 15: 5249–5259.
- 16. Dela Cruz CS, Liu W, HE CH, Jacoby A, Gornitzky A, et al. (2012) Chitinase 3-like-1 promotes Streptoccus Pneumoniae killing and augments host tolerance to lung antibacterial responses. Cell Host Microbe 12: 34–46.
- 17. Saidi A, Javerzat S, Bellahcene A, De Vos J, Bello L, et al. (2008) Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma. Int J Cancer 122: 2187–2198.
- 18. Shao R, Hamel K, Petersen L, Cao OJ, Arenas RB, Bigelow C, et al. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 28: 4456–4468.
- 19. Kawada M, Seno H, Kanada K, Nakanishi Y, Akitake R, Komekado H, et al. Chitinase 3-like-1 promotes macrophage recruitment and angiogenesis in colorectal cancer. Oncogene 31: 3111–23.
- 20. Chen C-C, Llado V, Eurich K, Tran HT, Mizoguchi E (2011) Carbohydrate-binding motif in chitinase 3-like 1 (CHI3L1/YKL-40) specifically activates Akt signaling pathway in colonic epithelial cells. Clin Immunol 140: 268–275.
- 21. Lee CG, Hartl D, Lee GR, Koller B, Matsuura H, et al. (2009) Role of breast regression protein 39 (BRP-39)/Chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med 206: 1149–1166.
- 22. Chang ST, Zahn JM, Horecka J, Kunz PL, Ford JM, et al. (2009) Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. J Translational Med 7: 105.
- 23. Johansen JS, Bojesen SE, Mylin AK, Frikke-Schmidt R, Price PA, et al. (2009) Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population. J Clin Oncol 27: 572–578.
- 24. Wigmore SJ, Fearon KCH, Sangster K, Maingay JP, Garden OJ, et al. (2002) Cytokine regulation of constitutive production of interleukin-8 and -6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer. Int J Oncol. 4: 881–886.
- 25. Trikha M, Corringham R, Klein B, Rossi JF (2003) Targeted anti-interleukin-6 monoklonal antibody therapy for cancer: A review of the rationale and clinical evidence. Clin Cancer Res 9: 4653–4665.
- 26. Martignoni ME, Kunze P, Hildebrandt W, Künzli B, Berberat P, et al. (2005) Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. Clin Cancer Res 16: 5802–5808.
- 27. Miyamoto Y, Hosotani R, Doi R, Wada M, Ida J, et al. (2001) Interleukin-6 inhibits radiation induced apoptosis in pancreas cancer cell. Anticancer Res 21: 2449–2456.
- 28. Barber MD, Fearon KC, Ross JA (1999) Relationship of interleukin-6, soluble interleukin-6 receptor and tumor necrosis factor receptor to the acute-phase response in advanced pancreatic cancer. Clin Science 96: 83–87.
- 29. Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R (2004) Cytokines in pancreatic carcinoma. Correlation with phenotypic characteristics and prognosis. Cancer 101: 2727–2736.
- 30.
Schultz NA, Johnsson A, Johansen JS, Christensen IJ, Gunnlaugsson A, et al.. (2013) Increases in plasma YKL-40 and IL-6 during chemotherapy of patients with pancreatic cancer and other upper gastrointestinal adenocarcinomas are associated with short survival. Manuscript submitted.
- 31. Bojesen SE, Johansen JS, Nordestgaard BG (2011) Plasma YKL-40 levels in healthy subjects from the general population. Clin Chim Acta 412: 709–712.
- 32. Knudsen LS, Christensen IJ, Lottenburger T, Svendsen MN, Nielsen HJ, et al. (2008) Pre-analytical and biological variability in circulating IL-6 in healthy subjects and patients with rheumatoid arthritis. Biomarkers 13: 59–78.
- 33. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2006) Reporting recommendations for tumor marker prognostic studies (Remark). Breast Cancer Res Treatment 100: 229–235.
- 34. Schultz NA, Johansen JS (2010) YKL-40-A protein in the field of translational medicine: A role as biomarker in cancer patients. Cancers 2: 1453–1491.
- 35. Høgdall EVS, Ringholt M, Høgdall CK, Christensen IJ, Johansen JS, et al. (2009) YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer 9: 8.
- 36. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144: 646–674.
- 37. Pietra K, Östman A (2010) Hallmarks of cancer: Interactions with the tumor stroma. Exp Cell Res 316: 1324–1331.
- 38.
Hanahan D, Coussens LM (2012) Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell 21; 309–322.
- 39. De Visser KE, Eichten A, Coussen LM (2006) Paradoxial role of the immune system during cancer development. Nat Rev Cancer 6: 24–37.
- 40.
Hamilton SR, Aaltonen LR (2000) World health organisation classification of tumors. Pathology and genetics of tumors of the gastrointestinal tract. IARC Press: Lyon 2000; 219–250.
- 41. Ringsholt M, Høgdall EV, Johansen JS, Price PA, Cristensen LH (2007) YKL-40 protein expression in normal adult human tissue - an immunohistochemichal study. J Mol Histol. 38: 33–43.
- 42. Recklies AD, White C, Ling H (2002) The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J 365: 119–126.
- 43. Ernst M, Putoczki TL (2012) Stat3: linking inflammation to (gastrointestinal) tumourigenesis. Clin Exp Pharmacol Physiol 39: 711–718.
- 44. Yang JD, Kim E, Pedersen RA, Kim WR, Pungapong S, et al. (2010) Utility of serum YKL-40 as a tumor-specific marker of hepato-biliary malignancies. Gut Liver 4: 537–542.
- 45. Algül H, Treiber M, Lesina M, Schmid RM (2007) Mechanisms of disease: Chronic inflamation and cancer in the pancreas - a potential role for pancreatic stellate cells. Nat Clin Pract Gastroenterol Hepatol 8: 454–462.
- 46. Fujita J, Tsunjinaka T, Yano M, Ebisui C, Saito H, et al. (1996) Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-Ubiquitin-dependent proteolytic pathways. Int J Cancer 68: 637–643.
- 47. Tsujinaka T, Fujita J, Ebisui C, Yano M, Kominami E, et al. (1996) Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest 97: 244–249.
- 48. Wu C, Miao X, Huang L, Che X, Jiang G, et al. (2012) Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. Nature Genetics 44: 62–66.
- 49.
He M, Wu C, Xu J, Guo H, Yang H, et al.. (2013) A genome wide association study of genetic loci that influence tumour biomarkers cancer antigen 19–9, carcinoembryonic antigen and α fetoprotein and their associations with cancer risk. Gut. Epub ahead of print. https://doi.org/10.1136